行情

DBVT

DBVT

DBV Tech
NASDAQ

实时行情|Nasdaq Last Sale

6.06
-0.19
-3.04%
休市 16:00 06/18 EDT
开盘
6.07
昨收
6.25
最高
6.17
最低
6.06
成交量
2.62万
成交额
--
52周最高
7.38
52周最低
1.350
市值
6.66亿
市盈率(TTM)
-4.1135
分时
5日
1月
3月
1年
5年
周一盘前交易中12支医疗保健股上涨
 
Benzinga · 05/24 12:10
周五盘前交易中的12种医疗保健股
 
Benzinga · 05/21 12:13
欧洲ADR在周五交易中走高
MT Newswires · 05/21 11:17
欧洲ADR在周三交易中走低
MT Newswires · 05/19 11:34
10-Q:DBV TECHNOLOGIES SA
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 05/05 20:18
昨天的64个最大动作
Gainers
Benzinga · 05/05 09:59
周二中午交易的44只股票
Gainers
Benzinga · 05/04 16:00
周二盘前交易中的26只股票
Gainers
Benzinga · 05/04 11:01
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解DBVT最新的财务预测,通过DBVT每股收益,每股净资产,每股现金流等数据分析DBV Tech近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测DBVT价格均价为9.42,最高价位16.56,最低价为1.948。
EPS
机构持股
总机构数: 95
机构持股: 4,016.26万
持股比例: 36.55%
总股本: 1.10亿
类型机构数股数
增持
12
210.91万
建仓
11
196.53万
减持
12
76.27万
平仓
4
29.11万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-1.19%
制药与医学研究
-0.98%
高管信息
Chairman/Chief Executive Officer/Director
Pierre-Henri Benhamou
Chief Operating Officer
David Schilansky
Executive Vice President/General Counsel
Joan Schmidt
Chief Scientific Officer
Hugh Sampson
Vice President - Research & Development
Lucie Mondoulet
Vice President - Business Development
Nathalie Donne
Director of Marketing
Veronique Foutel
Other
Wence Agbotounou
Other
Bertrand Dupont
Other
Laurent Martin
Other
Pascale Ehouarn
Director
Michel de Rosen
Director
George Horner
Director
Mailys Ferrere
Director
Didier Hoch
Director
Chahra Louafi
Director
Rafaele Tordjman
暂无数据
DBVT 简况
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

微牛提供DBV Technologies SA(NASDAQ-DBVT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的DBVT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易DBVT股票基本功能。